Be Bio to Collaborate with Resilience to Manufacture Its Engineered B Cells for Rare Diseases

Cell therapy drug developer Be Biopharma and contract manufacturer National Resilience have entered a strategic collaboration to advance initial programs in Be Bio’s rare disease pipeline.

Be Bio’s proprietary engineered B Cell Medicines (BeCM) platform taps into the natural power of the human B cell to create a new class of autologous and allogeneic cellular medicines to produce therapeutic proteins in vivo without toxic pre-conditioning that are durable and redosable.

Both companies are investing to drive innovation and reliability in cell therapy manufacturing, a critical success factor for broad and meaningful patient impact. As part of this, Resilience will dedicate personnel solely to produce and supply Good Manufacturing Practices (GMP)-grade viral vector and cell therapy drug product for the initial programs in Be Bio’s rare disease pipeline. Through a creative cost and risk-sharing model, Resilience will be responsible for manufacturing costs and receive potential future milestones and royalties.

“This deal allows us to drive GMP manufacturing with an outstanding partner, and in a capital efficient manner,” said Joanne Smith-Farrell, CEO of Be Bio. “Resilience’s broad manufacturing capabilities, strong collaborative spirit and dedicated resources to our platform, make them an ideal partner for our BeCM programs.”

Resilience will apply its pioneering bioprocessing solutions and network of cell therapy sites to lead clinical GMP manufacturing of both the viral vector and the cell therapy drug product for Be Bio’s initial rare disease programs to support first-in-human clinical trials.

“This collaboration shows our excitement for the promising science of Be Bio’s proprietary BeCM platforms, and our confidence in their expertise to deliver transformative cell therapies,” said Rahul Singhvi, CEO of Resilience. “By working alongside Be Bio early in the drug development process, we aim to accelerate the development of their B cell medicines with the potential to unlock a pipeline of product candidates across a variety of serious diseases.”

Photo: Joanne Smith-Farrell, CEO of Be Bio

Author: Rare Daily Staff